A Phase I, randomised, double-blind, placebo-controlled, single centre, single-dose escalation study to investigate the safety, tolerability, and pharmacodynamics of subcutaneously administered DEN-181 in adult patients with ACPA+ rheumatoid arthritis on stable treatment with methotrexate.
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2018
At a glance
- Drugs DEN 181 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Dendright
- 15 Mar 2018 Planned End Date changed from 14 Jun 2019 to 23 Jul 2018.
- 15 Mar 2018 Status changed from not yet recruiting to recruiting.
- 24 Oct 2017 New trial record